PreComb Therapeutics has closed its 1.3m CHF Pre-Series A Round. Biotech and deep tech-focused venture capital firms LongeVC and Kinled, in addition to family offices and private investors, participated in the investment. PreComb is developing an evidence-based therapy prediction for cancer drug discovery and therapy guidance using its patented 3DTwin technology.
Cancer remains one of the leading killers, with about 10 million deaths worldwide attributed to the disease in 2020. While personalised medicine is gaining traction in other medical fields, only 5%–10% of cancer patients currently benefit from customised treatment plans matching their unique genetic profile.
PreComb’s groundbreaking technology generates 3D tumour twins that mimic the behaviour and characteristics of the original tumour. The 3D microtumor then undergo AI-supported testing using a broad range of cancer drugs to determine which treatments will be most effective for an individual cancer patient. In the future, physicians will be able to use PreComb to conduct fully automated tests directly in their clinics for rapid results and direct treatment planning.
For the first time, a fully automated point-of-care solution is being developed for determining drug sensitivity or resistance directly in the clinic. Its ability to routinely test entire portfolios of cancer drugs and drug combinations in large-scale, making the technology a universal tool from drug discovery to guiding therapies.
“Cancer is an incredibly individualised disease,” said Jens M. Kelm, CEO and co-founder of PreComb. “Success of treatment depends largely on the unique tumour profile as well as the patient's biology. PreComb removes the guesswork from treatment protocols to ensure patients receive therapies tailored to their unique needs. We look forward to working with our new investors to advance our technology’s capabilities and reach.”
LongeVC Managing Partner and co-founder Sergey Jakimov said, “Personalised medicine is the future of healthcare. PreComb is using this technology to transform the narrative on cancer treatment and help individuals live longer and healthier lives post-diagnosis. We are proud to back their industry-defining work in oncology.”
Chairman of Kinled Patrick Aisher said, “PreComb will not only help patients receive the best treatments available but also serve as an invaluable resource for physicians and drug developers. By investing in their technology, we aim to unlock a greater understanding of cancer medicine for all.”
(Press release / SK)
Picture: PreComb Coroprate Video
Please login or sign up to comment.
Commenting guidelines